Lokeren, Belgium

Robin Temmerman

This inventor holds 1 USPTO granted patent and 3 EPO patents. Top assignee: Devan Chemicals Nv. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robin Temmerman. Retrieved from https://idiyas.com/inventor/robin-temmerman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Robin Temmerman

Robin Temmerman is an inventor based in Berlare, Belgium. He is currently associated with Heiq Chrisal NV, a company known for its innovative solutions in the field of antimicrobial technologies. Despite having no patents to his name, Temmerman's contributions to his field are noteworthy.

Latest Patents

As of now, Robin Temmerman holds 1 patents. This may reflect his focus on collaborative projects and research rather than individual patent filings.

Career Highlights

Throughout his career, Temmerman has been involved in various projects that emphasize the importance of sustainability and health. His work at Heiq Chrisal NV showcases his commitment to developing products that enhance hygiene and safety in everyday life.

Collaborations

Temmerman collaborates closely with his coworker, Corrie Gielen. Together, they work on innovative projects that aim to push the boundaries of antimicrobial technology.

Conclusion

In summary, Robin Temmerman is a dedicated inventor whose work at Heiq Chrisal NV highlights the importance of innovation in health and safety. His collaborative efforts with colleagues like Corrie Gielen further enhance the impact of his contributions in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…